Visit Watson-Marlow Fluid Technology Solutions at booth 3521 during INTERPHEX 2024 for exclusive technology previews and insights

Watson-Marlow Fluid Technology Solutions (WMFTS) will preview two new technologies at booth 3521 during INTERPHEX 2024, 16-18th April 2024, Javits Center, NYC, USA.

FemTech and Women’s Health start-ups urged to join Discovery Park’s growth programme, offering a support package worth over £50K

Discovery Park, Kent’s thriving life science community, has launched a special edition of their growth and support programme, Discovery Spark, for start-ups in FemTech and Women’s Health. Now open for applications, the programme offers tailored mentoring and support for start-ups, preparing founders for success in investment pitches. Companies will compete to win a support package worth over £50K, including 1 year of lab or office space at Discovery Park, alongside invaluable support from healthcare partners, Barclays Eagle Labs and six specialist prize partners.

CD Formulation Introduces Microneedle Patch Innovations for Enhanced Drug Delivery Efficiency

New Study Links Patients with Multiple Phenotypes to Higher Body Weight and BMI

Research from Mayo Clinic published in Nature’s International Journal of Obesity introduces new insights into obesity precision medicine for patients with more than one phenotype.

Alfa Chemistry Expands Offering of Polymer Fibers: Polyester Fiber, Polyamide Fiber, Aromatic Polyamide Fiber, and Polyacrylonitrile Fiber

Phreesia Announces Jack Callahan as New Chief Technology Officer

Phreesia, a leader in patient intake, outreach and activation, has named Jack Callahan as the company’s new Chief Technology Officer.

ENPICOM secures financing from BOP Capital, BOM Brabant Ventures and brings Dr. Colby Souders on board as a new investor

Investment to bolster international partnerships and advance AI-driven solutions for antibody discovery

CD Formulation Incorporates Phase Separation Method for Microsphere Production

ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors

ReciBioPharm partners with GeneVentiv Therapeutics to advance first AAV-based gene therapy for haemophilia patients

Alfa Chemistry's MS and NMR Center Enables Fast, Cost-Effective Laboratory Analytical Testing

ResultsCX Named ‘Promising Provider’ in Everest Group’s Service Provider Compass™ – Global Services Delivery from Mexico Report

Hovione and GEA Strengthen Partnership to Advance Continuous Tableting Technology

SPT Labtech to co-market streamlined NGS library preparation workflows for both PCR and PCR-free applications with Roche

Lindus Health Introduces Comprehensive “All-In-One CRO” Package for CNS, Neurology, and Psychiatric Clinical Trials

Lindus Health Introduces Comprehensive “All-In-One CRO” Package for CNS, Neurology, and Psychiatric Clinical Trials

DNAnexus Adds NVIDIA NIM and CUDA-X Microservices to Precision Health Data Cloud to Accelerate Drug Discovery and Improve Patient Care

DNAnexus is integrating new NVIDIA NIM and CUDA-X microservices to its Precision Health Data Cloud.

Bio-IT World: Venture, Innovation & Partnering Conference to Debut in Boston, Concurrent with 23rd Annual Bio-IT World Conference & Expo

Cambridge Healthtech Institute announces the final agenda for the inaugural Bio-IT World: Venture, Innovation & Partnering Conference—a gathering of leading investors, executives, research institutions, biotech and informatics innovators, startups, and strategics whose creative partnerships are catalyzing today’s drug discoveries. The April 17 Boston event, drawing heavily from leaders within the renowned Boston/Cambridge, Mass. biotech community, will be part of the 23rd annual Bio-IT World Conference & Expo April 15-17, which will attract more than 3,000 life science and IT innovators.

Alfa Chemistry Adds to Its Lineup of Derivatization Reagents for High-Performance Liquid Chromatography (HPLC)

AbbVie Launches Phase I Clinical Trial for ABBV-1882, Promising HIV Drugs Treatment Approach

The initiation of the phase I clinical trial for ABBV-1882 marks a significant milestone in the quest for novel HIV treatments. With its unique mechanism of action and potential to transform HIV management, ABBV-1882 represents a beacon of hope for individuals living with HIV and underscores AbbVie's unwavering commitment to advancing science for the benefit of patients worldwide.

Don't Miss: Huateng Pharma's Exhibit at CPHI Japan 2024

Hunan Huateng Pharmaceutical Co., Ltd is set to present its groundbreaking solutions at CPHI Japan 2024, showcasing expertise in PEG derivatives and CDMO services. Attendees are encouraged to visit Booth No. 4X-08 to explore cutting-edge offerings and engage with industry experts.

Join Biopharma PEG Scientific Inc. at PEGS Boston Summit and TIDES USA 2024

Biopharma PEG Scientific Inc. will showcase its latest high-purity polyethylene glycol (PEG) derivatives and custom synthesis solutions at Booth No. 718 in PEGS Boston Summit 2024 and at TIDES USA 2024 at Booth No. 935.